Interestingly, our study suggests that zidovudine, which targets O’-methyl transferase (Nsp16) can also bind to prolactin and can be of high significance in management of COVID-19 due to dual ability to affect Nsp16 and prolactin. The gene discussed is PRL; the disease is COVID-19.